News

Bringing physicians a new degree of control and conformability

Gore ASSURED Clinical Study results through 36 months demonstrate 100 percent closure success^*with the GORE^®CARDIOFORM ASD Occluder, and consistent safety outcomes^†across a broad range of ASD anatomies,^‡,1,2including patients with deficient retro-aortic rims.^§,2View the published study here.

W. L. Gore & Associates (Gore) announces FDA approval of an expanded indication for the GORE^® EXCLUDER^® Conformable AAA Endoprosthesis, now indicated for patients with aortic neck angulation ≤ 90° and a minimum length of 10 mm.

With improvements to the stent graft delivery system enabling a 1 Fr profile reduction  on the majority of sizes, the device now offers the most 6 Fr compatible configurations among balloon expandable stent grafts.

First off-the-shelf solution for treatment of complex aneurysmal disease involving the visceral aorta.

This study aims to compare the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis primary patency to bare metal stenting to evaluate superiority in treating complex iliac occlusive disease with the goal of informing practice guidelines around which modality is best suited for patients with this condition.

The first patient implant in the ARISE II Pivotal Study evaluation of the GORE® Ascending Stent Graft represents a major milestone in the development of endovascular treatment of the ascending aorta.

The Gore RELIEF Clinical Study is evaluating the safety and efficacy of transcatheter closure of patent foramen ovale (PFO) with the GORE® CARDIOFORM Septal Occluder for the relief of migraine headaches.

The Gore VBX FORWARD Clinical Study aims to compare the VBX Stent Graft primary patency to bare metal stenting to evaluate superiority in treating complex iliac occlusive disease.

FIRST U.S. PATIENT ENROLLED IN GORE® VIAFORT VASCULAR STENT ILIOFEMORAL PIVOTAL STUDY